March 13, 2018 PR-M03-18-NI-044
WILMINGTON, Mass.—(BUSINESS WIRE)—Charles River Laboratories International, Inc. (NYSE: CRL) recently announced several key expansions to its global Biologics Testing Solutions infrastructure to support the characterization, development, and release of biologics and biosimilars. Growth in this industry has led to increased demand for outsourced services, providing an opportunity for Charles River to enhance capacity and capabilities in support of client needs.
To increase its capacity and support higher demand, Charles River recently added a new, 73,000 square-foot facility on Devon Park Road in Wayne, Pennsylvania. This facility will more than double the laboratory space available at Charles River’s existing facilities in Malvern and King of Prussia, Pennsylvania.
Certain laboratory operations conducted at Charles River’s Malvern and King of Prussia sites will begin to move to Devon Park early in the third quarter of 2018. The formal transfer of assays will be done in phases, and during the transition, both the Malvern and King of Prussia facilities will remain fully operational to ensure there will be no interruption of services.
Additional Capacity and Capability Enhancements
Approved Quotes
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements include statements in this press release regarding future demand for drug discovery and development products and services, the timing of the move of certain laboratory operations to Charles River’s Devon Park site, the on-going enhancements and expansions to our Malvern, Shrewsbury, Erkrath, and Ballina sites, as well as the overall impact of these changes on the Biologics Testing Solutions business. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 13, 2018, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.
Charles River Laboratories International, Inc.
Investor Contact:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
amy.cianciaruso@crl.com
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.